Skip to main content
Erschienen in: Supportive Care in Cancer 3/2010

01.03.2010 | Original Article

Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population

verfasst von: Amanda Purcell, Jennifer Fleming, Sally Bennett, Bryan Burmeister, Terry Haines

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Multidimensional Fatigue Inventory (MFI) is a commonly used cancer-related fatigue assessment tool. Unlike other fatigue assessments, there are no published minimal clinically important difference (MCID) criteria for the MFI in cancer populations. MCID criteria determine the smallest change in scores that can be regarded as important, allowing clinicians and researchers to interpret the meaning of changes in patient’s fatigue scores. This research aims to improve the clinical utility of the MFI by establishing MCID criteria for the MFI sub-scales in a radiotherapy population.

Materials and methods

Two hundred ten patients undergoing radiotherapy were recruited to a single-centre prospective cohort study. Patients were assessed at three time points, at the start of radiotherapy, the end of radiotherapy and 6 weeks after radiotherapy completion. Assessment consisted of four clinically relevant constructs: (1) treatment impact on fatigue, (2) health-related quality of life, (3) performance status and (4) occupational productivity. These constructs were used as external or anchor-based measures to determine MCIDs for each sub-scale of the MFI.

Results

Multiple MCIDs were identified, each from a different perspective based on the constructs cited. Researchers seeking to use a generic MCID may wish to use a two-point reference for each MFI sub-scale as it was consistent across the pre- and post-radiotherapy comparison and occupational productivity anchors.

Conclusions

MCIDs validated in this study allow better interpretation of changes in MFI sub-scale scores and allow effect size calculations for determining sample size in future studies.
Literatur
1.
Zurück zum Zitat Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care 4:7. doi:10.1186/1472-684X-4-7 CrossRefPubMed Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care 4:7. doi:10.​1186/​1472-684X-4-7 CrossRefPubMed
4.
Zurück zum Zitat Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561. doi:10.1016/S0885-3924(02)00529-8 CrossRefPubMed Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561. doi:10.​1016/​S0885-3924(02)00529-8 CrossRefPubMed
7.
Zurück zum Zitat Drummond M, O’Brien B, Stoddart G, Torrance G (1993) Methods for the economic evaluation of health care programmes. Oxford Medical, New York Drummond M, O’Brien B, Stoddart G, Torrance G (1993) Methods for the economic evaluation of health care programmes. Oxford Medical, New York
8.
Zurück zum Zitat Ericsson A, Mannerkorpi K (2007) Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil 29:1665–1670CrossRefPubMed Ericsson A, Mannerkorpi K (2007) Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil 29:1665–1670CrossRefPubMed
10.
Zurück zum Zitat Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D et al (2008) Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 35:635–642PubMed Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D et al (2008) Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 35:635–642PubMed
20.
Zurück zum Zitat Portney L, Watkins M (2009) Foundations of clinical research. Pearson Prentice Hall, Upper Saddle River, pp 619–658 Portney L, Watkins M (2009) Foundations of clinical research. Pearson Prentice Hall, Upper Saddle River, pp 619–658
21.
Zurück zum Zitat Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S et al (2008) Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol 61:705–713CrossRefPubMed Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S et al (2008) Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol 61:705–713CrossRefPubMed
24.
Zurück zum Zitat Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing significance of health-related quality of life changes in clinical trials. Drug Inf J 37:23–31 Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing significance of health-related quality of life changes in clinical trials. Drug Inf J 37:23–31
26.
Zurück zum Zitat Smets E, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G et al (1998) Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 78:899–906PubMed Smets E, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G et al (1998) Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 78:899–906PubMed
27.
Zurück zum Zitat Smets E, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC (1998) Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907–912PubMed Smets E, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC (1998) Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907–912PubMed
28.
Zurück zum Zitat Strauss B, Brix C, Fischer S, Leppert K, Fuller J, Roehrig B et al (2007) The influence of resilience on fatigue in cancer patients undergoing radiation therapy (RT). J Cancer Res Clin Oncol 133:511–518. doi:10.1007/s00432-007-0195-z CrossRefPubMed Strauss B, Brix C, Fischer S, Leppert K, Fuller J, Roehrig B et al (2007) The influence of resilience on fatigue in cancer patients undergoing radiation therapy (RT). J Cancer Res Clin Oncol 133:511–518. doi:10.​1007/​s00432-007-0195-z CrossRefPubMed
29.
Zurück zum Zitat Turriziani A, Mattiucci GC, Montoro C, Ferro M, Maurizi F, Smaniotto D et al (2005) Radiotherapy-related fatigue: incidence and predictive factors. Rays 30:197–203PubMed Turriziani A, Mattiucci GC, Montoro C, Ferro M, Maurizi F, Smaniotto D et al (2005) Radiotherapy-related fatigue: incidence and predictive factors. Rays 30:197–203PubMed
30.
Zurück zum Zitat van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF (1996) Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 12:405–415PubMed van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF (1996) Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 12:405–415PubMed
Metadaten
Titel
Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population
verfasst von
Amanda Purcell
Jennifer Fleming
Sally Bennett
Bryan Burmeister
Terry Haines
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0653-z

Weitere Artikel der Ausgabe 3/2010

Supportive Care in Cancer 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.